Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. - Wikidata - awgldk - TriplyDB

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

http://www.wikidata.org/entity/Q34273968

about

Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia Adoptive T-Cell Immunotherapy Preventing stem cell transplantation-associated viral infections using T-cell therapy Immune response to HHV-6 and implications for immunotherapy Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.Engineering cord blood to improve engraftment after cord blood transplant.BK virus nephropathy in renal transplant recipients.Roseolovirus-associated encephalitis in immunocompetent and immunocompromised individuals.Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood A Simple Proteomics-Based Approach to Identification of Immunodominant Antigens from a Complex Pathogen: Application to the CD4 T Cell Response against Human Herpesvirus 6B Approach to drug-resistant cytomegalovirus in transplant recipients.Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios.A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation T cells for viral infections after allogeneic hematopoietic stem cell transplant Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.BK Polyomavirus and the Transplanted Kidney: Immunopathology and Therapeutic Approaches.Immunotherapy for opportunistic infections: Current status and future perspectives.Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials.Cytomegalovirus-specific T-cell therapies: current status and future prospects.Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know.Antigen-specific T cell therapies for cancer.The exciting "bench to bedside" journey of cell therapies for acute kidney injury and renal transplantation.Virus-specific T-cell therapy in solid organ transplantation.Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation.Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications.The "ABC" of Virus-Specific T Cell Immunity in Solid Organ Transplantation.CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

P2860

Q26740588-B6826444-1362-41E0-9A87-08C56371EA37 Q26782845-917F7510-07BA-4D64-B2CF-EAC7332DDCCF Q26801365-2EF39CCD-D184-4EFF-AAD8-D29EA1EDC03F Q26827409-63873BA2-691F-4308-8845-D1DC4AD51FC9 Q26861623-1636E15B-EC84-4A50-AC27-FF1F6C1B9522 Q27308832-209A6C38-7F5E-40E6-8D07-D925491F3CD1 Q28068378-794289D2-3579-4D15-A60B-77A6A30A2297 Q28079823-BEFC8431-3C96-4082-9B5B-BFE50844FFAC Q28085769-0C1E021E-FA93-4548-9DF3-665DA366E0AB Q29393780-77390840-9CC4-4FFE-8069-66302BEDB378 Q33633262-BF5AF767-44E6-4D29-9000-73BC71A9446F Q33703139-AD27DF2C-6F72-4EBD-829A-159134D5F8CA Q33766995-F041F0D7-2B95-4AFF-B047-8A2D40C62B73 Q34509585-E79A18F5-CE76-49B3-8A36-E2359A3A8E2D Q34537814-040C0539-91BE-4155-BCE6-8B267596361D Q35136456-C5340A4D-153A-4C4C-BB80-27474FEED348 Q35477534-7F4DD2B5-0D9F-4829-B962-79940D0CFD48 Q35582326-ADE99AFF-62CE-47F2-89E0-2877CAB16681 Q35850475-72278027-7084-4CBC-967A-8957962269CA Q35908691-BB104EF5-597D-4DBD-8834-FC80C6C57AD8 Q35958223-BA7ABC81-FF8E-4419-B7DA-544B483C6B11 Q35976599-A86C9AC7-4CCB-4B28-89D3-A5640F484CB2 Q36276185-D2A12A7F-A09D-4F3A-A944-80F5003A6371 Q36384572-1C5AE2D7-4010-47D9-AA3E-BC977A4EEB0D Q36903202-9A7C9226-A2E4-4C64-B492-C9B408426D2A Q36965855-3A035422-B36E-4EE3-9DB1-0D9F2AB40318 Q37058107-79A1D895-8501-4933-A405-24560FE7DD5A Q37203522-43488BE5-C6E1-4FC1-BCBC-5E586B984AC5 Q37375153-162CB477-F67F-44CB-B8F2-F32CAF18AF16 Q37509216-450E9721-443E-4196-9906-01C051FC06D7 Q38256992-17788458-A1CF-4EB2-AD72-A9E40E1A8C44 Q38365044-A1DA5B1D-9509-4FED-BC9A-CC5B410D2630 Q38444117-FFEE411C-4076-4F77-9CAF-E59BCB9482FC Q38544740-BF14276C-9BD6-4D24-9941-2F7DFA8218BB Q38558079-8DCE8733-2368-4D0F-9434-32F12E273552 Q38568902-08DAAC47-AB82-4535-8783-09D7B9D5A3F8 Q38640239-EC67FEE0-EA21-4E12-B7FA-E6BF9688C4EA Q38658670-372F2753-B88D-4E08-8E9B-727E6A903A45 Q38677902-F90431BF-5329-4A58-BE85-110605F20AA7 Q38702393-E691AA7C-E5DA-46DD-A888-3C03D90142B9

P2860

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

http://www.wikidata.org/entity/Q34273968

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@ast

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@en

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@nl

type

label

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@ast

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@en

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@nl

prefLabel

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@ast

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@en

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@nl

P1433

Q34273968-077B1FBB-33D6-4DCA-AA83-D3E15A1F8124

P1476

Q34273968-0E1DDC25-019C-47BA-9873-E3852E7C5320

P2093

Q34273968-10B6F466-704A-4EF2-A020-1DAC51112DAD

Q34273968-20147CC1-EC06-4B5D-A8CA-26DE3DA57DC5

Q34273968-2A439C83-2052-49C4-8703-57E3F991FD9B

Q34273968-2BD5EF85-9288-409F-8132-6E037872A086

Q34273968-387A146F-2E89-45C2-88AE-49B42989286E

Q34273968-569D26D4-240D-4FE7-B02E-CC7A656C866C

Q34273968-5B0F4F4D-B829-49CC-8055-4C8E0DF81A05

Q34273968-5E364CB9-7DE5-499F-A162-B72E4FC16575

Q34273968-9D7EA17F-33FA-4663-B1A7-086D7A4BADDA

Q34273968-9EEB1F8A-4C4A-4AD3-95CD-4CD13989CE51

P2860

Q34273968-0BA49A40-B6F4-4D16-8554-F3B66C41153F

Q34273968-0BBD649A-A390-403D-A41E-D06F342D3B20

Q34273968-0F11FA65-7DD8-4CEC-B704-B2D10456B430

Q34273968-100C511A-53D1-4D2F-95BB-FB5954127723

Q34273968-12E704B6-C38D-4B1C-986A-F015CC429C34

Q34273968-1AB37F28-4DC0-46B8-9588-914AF63F5559

Q34273968-1D92D6CE-4EB1-4762-91EC-2AD225BA6DE3

Q34273968-2005511E-7EFF-4256-B171-9F587C12BC38

Q34273968-222ADA97-E9C4-4D83-8490-8B9E91A01E30

Q34273968-22FCC2B3-F8CF-4D65-B4FA-B3BA0F99BB9A

P304

Q34273968-C146E942-73BF-4E97-921B-FA07472C3F57

P31

Q34273968-38EE7426-373A-4B83-85DA-F08303C9718A

P356

Q34273968-CBEF0495-1BE4-4097-9AA3-74B04C8EFCFF

P407

Q34273968-2FC308BE-5440-4EFC-B99D-EA562377BFAE

P433

Q34273968-CF88DAC8-DBE6-46CF-880D-49C0B7B4692D

P478

Q34273968-73B62518-FB08-466B-9F30-4265D7592D23

P577

Q34273968-452BD50C-B1EA-4880-B536-A406F51647D6

P698

Q34273968-51C8B7AD-310E-481D-9ED7-DB722878FCF0

P932

Q34273968-30B63029-423C-4947-BB31-727B237FF8C8

P356

SCITRANSLMED.3008825

P1433

Science Translational Medicine

P1476

Activity of broad-spectrum T c ...... nd HHV6 infections after HSCT.

@en

P2093

Adrian P Gee

http://www.w3.org/2001/XMLSchema#string

Anastasia Papadopoulou

http://www.w3.org/2001/XMLSchema#string

Ann M Leen

http://www.w3.org/2001/XMLSchema#string

Caridad Martinez

http://www.w3.org/2001/XMLSchema#string

Cliona M Rooney

http://www.w3.org/2001/XMLSchema#string

George Carrum

http://www.w3.org/2001/XMLSchema#string

Hao Liu

http://www.w3.org/2001/XMLSchema#string

Helen E Heslop

http://www.w3.org/2001/XMLSchema#string

Ifigenia Tzannou

http://www.w3.org/2001/XMLSchema#string

Juan F Vera

http://www.w3.org/2001/XMLSchema#string

P2860

Update on human herpesvirus 6 biology, clinical features, and therapy

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

P304

242ra83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3008825

http://www.w3.org/2001/XMLSchema#string

P407

P433

242

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24964991

http://www.w3.org/2001/XMLSchema#string

P932

4181611

http://www.w3.org/2001/XMLSchema#string